Novo Holdings’ early-stage investment and company creation team Novo Seeds has established a new portfolio company – Hemab – which will focus on the development of bispecific antibodies for rare bleeding disorders.
The company, co-founded by former Novo Nordisk executives Johan Faber and Søren Bjørn, has secured an exclusive license to certain intellectual property to develop a product within haemophilia and other rare bleeding disorders from Novo Nordisk.
Hemab has also scored an exclusive license to Genmab’s bispecific DuoBody platform technology, which will help the company to develop further novel therapies for ultra-rare bleeding disorders.
“We are very pleased to have Novo Seeds on board as investor and partner to accelerate the development of our exciting new technology platform,” said Johan Faber, co-founder and chief executive officer of Hemab.
“We are passionate about developing novel therapies for people with severe bleeding disorders that are in high need for a prophylactic treatment option that is effective, safe and convenient. With the hands-on support of Novo Seeds we have a strong foundation to realize our ambitions for patients with rare bleeding disorders,” he added.
Jørgen Søberg Petersen, Novo Seeds Partner, will join Henmab as chairman and Camilla Petrycer Hansen, Novo Seeds Senior Associate, will also join the board.
In addition, Benny Sørensen, will join the board as an independent non-executive director.
Sørensen currently serves as senior vice president, head of clinical development at Codiak BioSciences.
by Lucy Parsons
Source: pharmatimes.com
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
